Article | October 4, 2021

Achieving Cell And Gene Manufacturing Scalability: A Conversation With AVROBIO's Geoff MacKay

Source: Cytiva

By Cytiva

iStock-1268214384-cell-gene-virus

One of the greatest obstacles that gene therapy companies face is scale-up. Lentiviral gene therapies, still early in their clinical journey, also have that challenge, with companies racing to find the technologies and solutions necessary to achieve commercial success.

AVROBIO is a clinical-stage company pursuing investigational therapies in a handful of rare lysosomal disorders. Geoff MacKay, President and CEO of AVROBIO, believes we’re on the verge of innovations that will allow companies to scale transformational early-stage science into global therapeutic solutions.

“One of the elephants in the room is this: How do you take this petri dish science and mass produce pharmaceutical grade medicine?” AVRO and others are trying to tackle this problem, and it is one that MacKay says requires creativity and adaptability across every phase of development.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online